Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges. Raziye Piranlioglu
Semin Immunol. 2025 Jun 23;79:101975. doi: 10.1016/j.smim.2025.101975. Online ahead of print. ABSTRACT The pivotal involvement of the host immune system in cancer therapy has dramatically reshaped therapeutic paradigms, inaugurating the era of immunotherapy. Nonetheless, antigen-specific immunotherapies encounter substantial hurdles within the highly immunosuppressive microenvironment of glioblastoma (GBM), which thwarts antitumor T-cell immunity. Oncolytic viruses (OVs), … Read more